Kim Yeni, Cho Soo-Churl, Shin Min-Sup, Kim Jae-Won, Choi Sang-Chul, Kim Boong-Nyun
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Institute of Human Behavioral Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Curr Ther Res Clin Exp. 2009 Apr;70(2):173-83. doi: 10.1016/j.curtheres.2009.04.007.
The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder.
The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales.
Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms (U = 25.5; P = 0.028; r = -0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%).
The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.
本病例系列研究旨在评估阿立哌唑对患有早发性精神分裂症谱系障碍（EOSS）的韩国儿童及青少年的有效性和耐受性。
对接受阿立哌唑治疗的EOSS患者的病历进行回顾性分析。采用临床总体印象-疾病严重程度（CGI-S）和临床总体印象-改善情况（CGI-I）量表评估疾病严重程度的变化。
纳入22例儿童及青少年患者的数据（12例女孩，10例男孩；平均[标准差]年龄为14.0[2.4]岁）。阿立哌唑的平均（标准差）剂量为19.8（9.4）mg/d（中位数为18.7mg/d；众数为15、30mg/d），治疗持续时间为21至838天。从基线至终点，平均（标准差）CGI-S评分显著改善（从5.7[0.7]降至4.3[1.4]；P<0.001）。根据图表提取的CGI-I评分变化，与阳性症状相比，阴性症状的改善更为显著（U=25.5；P=0.028；r=-0.47）。5例患者（22.7%）因疗效不佳停用阿立哌唑，3例患者（13.6%）因出现治疗中出现的不良事件停药。
这项小型研究的结果表明，阿立哌唑对患有EOSS的韩国儿童及青少年减轻精神病性症状有一定疗效。
